Tuesday, November 10, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Ocular Changes in Patients Using Tirzepatide or Semaglutide

NCT07924618 · N/A · RECRUITING · Sponsor: Istanbul University · Conditions: Type 2 Diabetes Mellitus,

PR
By Priya Raman · Science Reporter
Nov 9 07:00 ETSource: ClinicalTrials.gov

From the source

Ocular Changes in Patients Using Tirzepatide or Semaglutide

NCT07924618 · N/A · RECRUITING · Sponsor: Istanbul University · Conditions: Type 2 Diabetes Mellitus, Obesity.

Read at clinicaltrials.gov
PeptiPrescribed peptides from $99/moSee all →